entinostat has been researched along with Cancer, Second Primary in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prebet, T | 1 |
| Sun, Z | 1 |
| Ketterling, RP | 1 |
| Zeidan, A | 1 |
| Greenberg, P | 1 |
| Herman, J | 1 |
| Juckett, M | 1 |
| Smith, MR | 1 |
| Malick, L | 1 |
| Paietta, E | 1 |
| Czader, M | 1 |
| Figueroa, M | 1 |
| Gabrilove, J | 1 |
| Erba, HP | 1 |
| Tallman, MS | 1 |
| Litzow, M | 1 |
| Gore, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Dose-Finding Trial of the Histone Deacetylase Inhibitor MS-275 (NSC 706995) in Combination With 5-Azacitidine (5AC, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMMoL) and Acute Myeloid Leukemia (AML)[NCT00101179] | Phase 1 | 63 participants (Actual) | Interventional | 2004-11-03 | Completed | ||
| A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasi[NCT00313586] | Phase 2 | 197 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Clinical response is defined as a complete response (CR), partial response (PR) or trilineage response (TR) graded according to the following criteria:~World Health Organization classification of the acute leukemias and myelodysplastic syndrome (by Bennett)~Myelodysplastic syndromes standardized response criteria: further definition (by Cheson et al.)~Report of an international working group to standardize response criteria for myelodysplastic syndromes (by Cheson et al.)" (NCT00313586)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2 - 5 years from study entry.
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (Azacitidine; Non-treatment-induced Cohort) | 0.32 |
| Arm B (Azacitidine + Entinostat; Non-treatment-induced Cohort) | 0.27 |
| Arm A (Azacitidine; Treatment-induced Cohort) | 0.46 |
| Arm B (Azacitidine + Entinostat; Treatment-induced Cohort) | 0.17 |
1 trial available for entinostat and Cancer, Second Primary
| Article | Year |
|---|---|
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2016 |
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2016 |
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2016 |
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2016 |